An experimental immunotherapy for early Alzheimer’s disease, called IBC-Ab002, has shown promise in a Phase 1b clinical trial involving 40 patients across multiple countries. Developed by ImmunoBrain and based on research from Israel’s Weizmann Institute, the treatment was found to be safe and well-tolerated, with biological activity linked to reduced neuronal damage. Unlike traditional therapies that target amyloid plaques, IBC-Ab002 addresses immune dysfunction as a disease driver. Initial findings suggest that restoring immune function could significantly impact Alzheimer’s and other neurodegenerative diseases, although larger trials are needed for further validation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ynetnews.com/health_science/article/ryqojtleze
